Hintergrund: Die zytoreduktive Chirurgie und die hypertherme intraperitoneale Chemotherapie spielen inzwischen eine zunehmend wichtige Rolle in der Therapie der Peritonealkarzinose bei zahlreichen Tumorentitäten. Methode: Die wichtigsten Selektionskriterien werden erläutert. Ergebnisse: Neben dem Alter und Allgemeinzustand sowie der Auswahl geeigneter Tumorentitäten spielt die Tumorlast, die möglichst exakt bereits vor der Operation abgeschätzt werden sollte, eine entscheidende Rolle. Schlussfolgerung: Entscheidend ist eine Selektion geeigneter Patienten, um den onkologischen Benefit zu steigern und die Morbidität zu verringern.

Keywords:
Peritonealkarzinose, Hypertherme intraperitoneale Chemotherapie, HIPEC, Selektion, Diagnostik
1.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363.
2.
Pyrhoenen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71: 587-591.
3.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. A multi-institutional study of 1290 patients. Cancer 2010;116:5608-5618.
4.
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575-1581.
5.
Yan TD, Deraco M, Baratti D, et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237-6242.
6.
Elias D, Honore C, Ciuchendea R, et al: Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 2008;95: 1164-1171.
7.
Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR: Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551-559.
8.
Sugarbaker PH: Epithelial appendiceal neoplasms. Cancer J 2009;15:225-235.
9.
Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359-374.
10.
Elias D, Gilly F, Boutitie F, et al: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63-68.
11.
da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006;203:878-886.
12.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-3292.
13.
Yonemura Y, Elnemr A, Endou Y, et al: Multi-disciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010;2:85-97.
14.
Koenigsrainer I, Aschoff P, Zieker D, Beckert S, Glatzle J, Pfannenberg C, Miller S, Hartmann JT, Schroeder TH, Bruecher BL, Koenigsrainer A: Selection criteria for peritonectomy with hyperthermic intraoperative chemotherapy (HIPEC) in peritoneal carcinomatosis. Zentralbl Chir 2008;133: 468-472.
15.
Yan TD, Sim J, Morris DL: Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2007;14:1807-1817.
16.
Quayyum A, Coakley FV, Westphalen AC, et al: Role of CT and MRI in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gyneco Oncol 2005;96:301-306.
17.
Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219-228.
18.
Testa A, Ludovisi M, Mascilini F, Di Legge A, Malaggese M, Faqotti A, Fanfani F, Salerno M, Ercoli A, Scambia G, Ferrandina G: Ultrasound evaluation of intra-abdominal sites of disease to predict the likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study. Ultrasound Obstet Gynecol 2012;39:99-105.
19.
Funicelli L, Travaini LL, Landoni F, Trifiro G, Bonello L, Bellomi M: Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET/CT. Abdom Imaging 2010;35:701-707.
20.
Forstner R: Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 2007;17:3223-3246.
21.
Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP: Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513-520.
22.
Pfannenberg C, Koenigsrainer I, Aschoff P, Oeksuez MO, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Weyhern CV, Brücher BL, Claussen CD, Koenigsrainer A: (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2009;16:1295-1303.
23.
Iafrate F, Ciolina M, Sammartino P, Baldassari P, Rengo M, Lucchesi P, Sibio S, Accarpio F, Di Giorgio A, Laghi A: Peritoneal carcinomatosis: imaging with 64-MDCT and 3T MRI with diffusion-weighted imaging. Abdom Imaging 2012;37:616-627.
24.
Souza FF, Jagganathan J, Ramayia N, Cirian J, Jackman D, Van den Abbeele A, Ros PR: Recurrent malignant peritoneal mesothelioma: radiological manifestations. Abdom Imaging 2010;35:315-321.
25.
Morita H, Aoki J, Taketomi A, Sato N, Endo K: Serous surface papillary carcinoma of the peritoneum: clinical, radiologic and pathologic findings in 11 patients. AJR Am J Roentgenol 2004;183:923-928.
26.
Low RN, Sigeti JS: MR imaging of peritoneal disease: comparison of contrast enhanced fast multi-planar spoiled gradient recalled and spin echo imaging. AJR 1994;163:1131-1140.
27.
Forstner R, Hricak H, Powell CB, et al: Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196:715-720.
28.
Low RN, Carter WD, Saleh F, et al: Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radiology 1995;195:391-400.
29.
Klumpp BD, Aschoff P, Schwenzer N, Fenchel M, Koenigsrainer I, Falch C, Bruecher B, Claussen CD, Koenigsrainer A, Pfannenberg C, Kramer U, Miller S: Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. Abdom Imaging 2012;37:834-842.
30.
Sato Y, Ichikawa T, Motosugi U, Kimura K, Sou H, Sano K, Araki T: Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI and contrast-enhanced MDCT. AJR Am J Roentgenol 2011;196:447-453.
31.
Glaspy JA, Hawkins R, Hoh CK, Phelps ME: Use of positron emission tomography in oncology. Oncology 1993;7:41-55.
32.
Kole AC, Nieweq OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, Vaalburg W, Vermey A: Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166.
33.
Klumpp BD, Schwenzer N, Aschoff P, Miller S, Kramer U, Claussen CD, Bruecher B, Koenigsrainer A, Pfannenberg C: Preoperative assessment of peritoenal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdom Imaging 2013;38:64-71.
34.
Rakheja R, Makis W, Hickeson M: Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT. Abdom Imaging 2012;37:304-308.
35.
Low RN: MR imaging of the peritoneal spread of malignancy. Abdom Imaging 2007;32:267-283.
36.
Zissin R, Hertz M, Shapiro-Feinberg M, et al: Primary serous papillary carcinoma of the peritoneum: CT findings. Clin Radiol 2001;56:740-745.
37.
De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, Cacciari N, Al-Nahhas A, Rubello D, Venturoli S, Fanti S: FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 2011;80:e98-103.
38.
Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, Schumberger M, Sigal R, Elias D: Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 2008;33:87-93.
39.
Priest AN, Gill AB, Kataoka M, McLean MA, Joubert I, Graves MJ, Griffiths JR, Crawford RAF, Earl H, Brenton JD, Lomas DJ, Sala E: Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med 2010;63:1044-1049.
40.
Garofalo A, Valle M: Laparoscopy in the management of peritoneal carcinomatosis. Cancer J 2009;15:190-195.
41.
Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D: The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:540-543.
42.
Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M: Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23:187-190.
43.
Valle M, Federici O, Garofalo A: Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am 2012;21:515-531.
44.
Iversen LH, Rasmussen PC, Laurberg S: Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285-292.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.